NervGen Pharma Corp.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving NervGen Pharma Corp. now
Current reporting with the operating signal separated from the noise.
NervGen Pharma Corp.: NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
The story matters when it changes NervGen Pharma Corp.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.NervGen Pharma Corp. Announces Overnight Marketed Equity Offering
The story matters when it changes NervGen Pharma Corp.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest NGEN filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
NervGen Pharma Corp., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →